- Home
- CYRX vs MYGN Comparison
CYRX vs MYGN Comparison
Compare CYRX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | MYGN |
|---|---|---|
| Founded | 1999 | 1991 |
| Country | United States | United States |
| Employees | 1100 | 2700 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.6M | 481.6M |
| IPO Year | 2008 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CYRX | MYGN |
|---|---|---|
| Price | $8.05 | $5.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $12.94 | $8.06 |
| AVG Volume (30 Days) | 341.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | $176,177,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $9.71 | $7.19 |
| Revenue Next Year | $9.56 | $5.64 |
| P/E Ratio | $4.99 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $4.63 | $3.76 |
| 52 Week High | $11.45 | $11.44 |
Technical Indicators
Market Signals| Indicator | CYRX | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 51.59 |
| Support Level | $6.57 | $4.82 |
| Resistance Level | $8.45 | $5.67 |
| Average True Range (ATR) | 0.51 | 0.39 |
| MACD | 0.04 | 0.13 |
| Stochastic Oscillator | 25.71 | 64.60 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.